CME

Faculty: Joshua Richter, MD

Faculty: Noopur Raje, MD

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Joshua Richter, MD

Faculty: Noopur Raje, MD

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Joshua Richter, MD

Faculty: Sagar Lonial, MD, FACP

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Sagar Lonial, MD, FACP

Faculty: Noopur Raje, MD

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Host: Brian P. McDonough, MD, FAAFP

Guest: Silvio Inzucchi, MD

Guest: Darren McGuire, MD, MHSc

Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management.

Faculty: Joshua Richter, MD

Faculty: Sagar Lonial, MD, FACP

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Noopur Raje, MD

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Sagar Lonial, MD, FACP

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Faculty: Sagar Lonial, MD, FACP

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Host: Maria Fleseriu, MD, FACE

Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities. Do you know how to effectively treat acromegaly to increase your patients’ quality of life? Tune in for an overview of the latest data.